| COVID-19 |
1 |
1 |
| Immunization |
0 |
0.98 |
| Biologic Therapy |
0 |
0.37 |
| Cancer |
0 |
0.33 |
| Antineoplastic Drug |
0 |
0.26 |
| Blood |
0 |
0.26 |
| HIV Infection |
0 |
0.17 |
| Leukemia |
0 |
0.13 |
| Lymphoma |
0 |
0.13 |
| Vaccines |
0 |
0.99 |
| Social Determinants of Health |
0 |
0.07 |
| Social Distancing |
0 |
0.07 |
| Tyrosine Kinase Inhibitor |
0 |
0.06 |
| Combination Chemotherapy |
0 |
0.05 |
| Acute Respiratory Distress Syndrome |
0 |
0.03 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.03 |
| Chemotherapy |
0 |
0.03 |
| Grant |
0 |
0.03 |
| Hand |
0 |
0.03 |
| Immunocompromise |
0 |
0.03 |
| Memory |
0 |
0.03 |
| Monoclonal Antibody |
0 |
0.03 |
| New York |
0 |
0.03 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.03 |
| Pandemic |
0 |
0.03 |
| Severe Acute Respiratory Syndrome |
0 |
0.03 |
| Stress |
0 |
0.03 |
| T-Lymphocyte |
0 |
0.03 |
| Third Space |
0 |
0.03 |
| Tyrosine Kinase |
0 |
0.03 |